Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Duramed Research
The overall study duration for each patient will be approximately 8 months, which includes a screening period of approximately 4 weeks; a treatment period of approximately six months (six,28-day cycles); and a follow-up visit approximately 4 weeks after completion of study drug.
Age
18–45
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Premenopausal
Not pregnant or breastfeeding
Sexually active at risk of pregnancy
You may not be if
Any contraindication to the use of oral contraceptives
Pregnancy within the last 3 months
Smoking \> 10 cigarettes per day
Clareo Health | Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive
